RxDoctor Payments Data

Gina Vaccaro, MD

Medical Oncology · Cookeville, TNNPI 1700960671

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $176,744 of the $247,854 with a category attached, or 71.3%. Incyte Corporation accounts for 74.1% of it on its own, with 58 other manufacturers making up the rest. 2025 is the largest year on record at $77,905, more than ten times the $3,399 reported in 2019. Among medical oncology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$247,854in general payments, 2019–2025

Across 545 payments — averaging $454.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$184K
  • Astellas Pharma US Inc$27K
  • AstraZeneca$9K
  • Partner Therapeutics, Inc.$6K
  • Taiho Oncology, Inc.$3K
  • GSK$3K
  • plus $16K from 53 others
$4,549,379in research payments, 2019–2025

Across 583 payments — averaging $7803.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$1.1M
  • Merck$1M
  • Pfizer$853K
  • Seagen Inc.$557K
  • Amgen$411K
  • EMD Serono, Inc.$180K
  • plus $488K from 9 others

What the payments were for

  • Consulting fees$25,21910%
  • Speaking & faculty fees$176,74471%
  • Travel & lodging$32,51613%
  • Food & beverage$12,6065%
  • Education$7700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Incyte Corporation193$183,777
Astellas Pharma US Inc37$27,197
AstraZeneca(2 entities)31$8,743
Partner Therapeutics, Inc.14$6,183
Taiho Oncology, Inc.6$3,142
GSK14$2,882
Array Biopharma Inc2$2,536
Helsinn Therapeutics (U.S.), Inc.1$2,171
Merck6$1,636
Exelixis Inc.10$1,444
Astrazeneca UK Limited9$1,275
Daiichi Sankyo Inc.24$723
E.r. Squibb & Sons, L.L.C.13$445
Pfizer13$410
Regeneron Healthcare Solutions, Inc.8$408
Johnson & Johnson13$328
Eisai Inc.9$325
AbbVie8$281
Bayer11$245
Gilead8$231
Beone Medicines USA, Inc.5$210
Pharmacosmos Therapeutics Inc.6$201
Foundation Medicine, Inc.4$196
Bristol Myers Squibb5$188
Genentech USA, Inc.4$187
Novartis9$175
Sanofi6$158
Sobi, Inc4$158
Takeda Pharmaceuticals U.S.A., Inc.4$149
Karyopharm Therapeutics Inc.3$143
Tersera Therapeutics LLC5$112
Legend Biotech USA Inc.3$110
Sanofi US Services Inc.1$103
Ipsen Biopharmaceuticals, Inc3$100
Seagen Inc.1$99
Kyowa Kirin, Inc.4$95
Genmab U.S., Inc.4$94
AVEO Pharmaceuticals, Inc.3$84
Rigel Pharmaceuticals, Inc.3$79
Jazz Pharmaceuticals Inc.4$73
Dendreon Pharmaceuticals LLC2$66
Amgen1$62
Beigene USA, Inc.3$62
Boehringer Ingelheim3$57
Lilly USA, LLC3$55
Servier Pharmaceuticals LLC1$51
Fennec Pharmaceuticals, Inc.3$51
ADC Therapeutics America, Inc.2$50
Pharmaessentia USA Corporation2$45
EMD Serono, Inc.2$41
Geron Corporation2$39
Puma Biotechnology, Inc.2$38
Deciphera Pharmaceuticals Inc.1$29
Novocure Inc.1$22
Stemline Therapeutics Inc.1$20
Sumitomo Pharma America, Inc.1$20
Pharmaand GmbH2$17
Agios Pharmaceuticals, Inc.1$17
Verity Pharmaceuticals Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$247,854 in reported general payments places this provider in the 90th percentile of 101 medical oncology providers in Tennessee.

See all medical oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$3,344,147
Medicare patients
349
Services billed
141,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$23,321
Prochlorperazine Maleate111$1,595
Ondansetron OdtOndansetron57$952
Dexamethasone35$405
Omeprazole19$329
Mirtazapine20$245
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$226
Hydroxyurea12$223
Oxycodone Hcl15$194
Olanzapine46$177
Prednisone12$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$410$23,32124 claims
Lilly USA, LLCOlanzapine$55$17746 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 101 medical oncology providers in Tennessee.

Other medical oncology in Cookeville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →